Your browser doesn't support javascript.
Recent infection with HCoV-OC43 may be associated with protection against SARS-CoV-2 infection.
Lavell, A H Ayesha; Sikkens, Jonne J; Edridge, Arthur W D; van der Straten, Karlijn; Sechan, Ferdyansyah; Oomen, Melissa; Buis, David T P; Schinkel, Michiel; Burger, Judith A; Poniman, Meliawati; van Rijswijk, Jacqueline; de Jong, Menno D; de Bree, Godelieve J; Peters, Edgar J G; Smulders, Yvo M; Sanders, Rogier W; van Gils, Marit J; van der Hoek, Lia; Bomers, Marije K.
  • Lavell AHA; Amsterdam UMC Location Vrije Universiteit Amsterdam, Department of Internal Medicine, De Boelelaan 1117, 1081 HV, Amsterdam, the Netherlands.
  • Sikkens JJ; Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands.
  • Edridge AWD; Amsterdam UMC Location Vrije Universiteit Amsterdam, Department of Internal Medicine, De Boelelaan 1117, 1081 HV, Amsterdam, the Netherlands.
  • van der Straten K; Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands.
  • Sechan F; Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands.
  • Oomen M; Amsterdam UMC Location University of Amsterdam, Department of Medical Microbiology and Infection Prevention, Laboratory of Experimental Virology, Meibergdreef 9, 1105 AZ, Amsterdam, the Netherlands.
  • Buis DTP; Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands.
  • Schinkel M; Amsterdam UMC Location University of Amsterdam, Department of Medical Microbiology and Infection Prevention, Laboratory of Experimental Virology, Meibergdreef 9, 1105 AZ, Amsterdam, the Netherlands.
  • Burger JA; Amsterdam UMC Location University of Amsterdam, Department of Internal Medicine, Meibergdreef 9, 1105 AZ, Amsterdam, the Netherlands.
  • Poniman M; Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands.
  • van Rijswijk J; Amsterdam UMC Location University of Amsterdam, Department of Medical Microbiology and Infection Prevention, Laboratory of Experimental Virology, Meibergdreef 9, 1105 AZ, Amsterdam, the Netherlands.
  • de Jong MD; Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands.
  • de Bree GJ; Amsterdam UMC Location University of Amsterdam, Department of Medical Microbiology and Infection Prevention, Laboratory of Experimental Virology, Meibergdreef 9, 1105 AZ, Amsterdam, the Netherlands.
  • Peters EJG; Amsterdam UMC Location Vrije Universiteit Amsterdam, Department of Internal Medicine, De Boelelaan 1117, 1081 HV, Amsterdam, the Netherlands.
  • Smulders YM; Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands.
  • Sanders RW; Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands.
  • van Gils MJ; Center for Experimental and Molecular Medicine (CEMM), Amsterdam UMC Location Academic Medical Center, Meibergdreef 9, 1105 AZ, Amsterdam, the Netherlands.
  • van der Hoek L; Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands.
  • Bomers MK; Amsterdam UMC Location University of Amsterdam, Department of Medical Microbiology and Infection Prevention, Laboratory of Experimental Virology, Meibergdreef 9, 1105 AZ, Amsterdam, the Netherlands.
iScience ; 25(10): 105105, 2022 Oct 21.
Article in English | MEDLINE | ID: covidwho-2007784
ABSTRACT
Antibodies against seasonal human coronaviruses (HCoVs) are known to cross-react with SARS-CoV-2, but data on cross-protective effects of prior HCoV infections are conflicting. In a prospective cohort of healthcare workers (HCWs), we studied the association between seasonal HCoV (OC43, HKU1, 229E and NL63) nucleocapsid protein IgG and SARS-CoV-2 infection during the first pandemic wave in the Netherlands (March 2020 - June 2020), by 4-weekly serum sampling. HCW with HCoV-OC43 antibody levels in the highest quartile, were less likely to become SARS-CoV-2 seropositive when compared with those with lower levels (6/32, 18.8%, versus 42/97, 43.3%, respectively p = 0.019; HR 0.37, 95% CI 0.16-0.88). We found no significant association with HCoV-OC43 spike protein IgG, or with antibodies against other HCoVs. Our results indicate that the high levels of HCoV-OC43-nucleocapsid antibodies, as an indicator of a recent infection, are associated with protection against SARS-CoV-2 infection; this supports and informs efforts to develop pancoronavirus vaccines.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines Language: English Journal: IScience Year: 2022 Document Type: Article Affiliation country: J.isci.2022.105105

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines Language: English Journal: IScience Year: 2022 Document Type: Article Affiliation country: J.isci.2022.105105